Managing Aggregate Spend Compliance and Transparency for Life Sciences Organizations across the Enterprise

WEBINAR: JULY 24 | 11AM ET/8 AM PT Join Pegasystems and Cognizant as they instruct how to accurately and efficiently capture relevant payments and other transfers of value, to meet the requirements of The US Physicians Sunshine Act and similar global regulations. Register Now! Sign up for our FREE newsletter for more news like this sent to your inbox! James Hughes, a public policy professor at Rutgers, tells The Record that the state lost its edge as the old focus on traditional small molecules gave way to the current focus on biologics. The state's aging research facilities lost their rep for cutting-edge research, but Hughes believes that a recent move to merge several colleges could put New Jersey back on track. The idea is to create the kind of academic center of excellence that has drawn Big Pharma R&D to Boston/Cambridge, San Francisco and Cambridge in the U.K. Theoretically, that's a workable approach, but leading universities have stolen a march on New Jersey's academic institutions, and making up ground in this field is notoriously hard and slow. Once off the beaten path in biopharma, it can take many years to find the road again.